Difficulty: Medium
Average Score: 86%
Practice
The only FDA-approved medication for obesity in children
Correct answer
A
Rationale
The correct answer is A) orlistat. Orlistat is the only FDA-approved medication for obesity in children under 16 years old. Orlistat works by blocking the absorption of fat in the gastrointestinal tract, leading to weight loss. It is generally well-tolerated and has been shown to be effective in managing obesity in pediatric patients.
Option B) phentermine is not FDA-approved for use in children under 16 years old. Phentermine is typically prescribed for short-term weight loss in adults and is not recommended for pediatric use due to potential adverse effects on growth and development.
Option C) topiramate is not FDA-approved for pediatric obesity. While it has been used off-label for weight management in some cases, its safety and efficacy in children for this indication have not been well established.
Option D) amylin is not an FDA-approved medication for pediatric obesity. Amylin is a hormone involved in regulating blood sugar levels and is not indicated for weight loss in children.
In an educational context, it is important for healthcare professionals to be aware of the limited options for pharmacological management of obesity in pediatric patients. Understanding the available medications, their mechanisms of action, and their approved indications can help in making informed decisions when treating children with obesity. Additionally, emphasizing the importance of lifestyle modifications, such as diet and exercise, as first-line interventions is crucial in managing pediatric obesity effectively.
Option B) phentermine is not FDA-approved for use in children under 16 years old. Phentermine is typically prescribed for short-term weight loss in adults and is not recommended for pediatric use due to potential adverse effects on growth and development.
Option C) topiramate is not FDA-approved for pediatric obesity. While it has been used off-label for weight management in some cases, its safety and efficacy in children for this indication have not been well established.
Option D) amylin is not an FDA-approved medication for pediatric obesity. Amylin is a hormone involved in regulating blood sugar levels and is not indicated for weight loss in children.
In an educational context, it is important for healthcare professionals to be aware of the limited options for pharmacological management of obesity in pediatric patients. Understanding the available medications, their mechanisms of action, and their approved indications can help in making informed decisions when treating children with obesity. Additionally, emphasizing the importance of lifestyle modifications, such as diet and exercise, as first-line interventions is crucial in managing pediatric obesity effectively.